PUMA Biotechnology reported a notable increase in operating income and net income through 2025 despite flat revenue largely supported by sales of its flagship drug NERLYNX. The company’s strategic reliance on NERLYNX’s U.S. sales, combined with sub-license agreements abroad, underpins its commercial footprint but limits global control. Development of alisertib represents a potential growth avenue yet comes with significant clinical and capital risks. Investor caution persists given subdued forward guidance and the financial covenants impacting operational flexibility. Sustaining profitability amid these constraints will depend on efficient capital allocation, pipeline progress, and navigating regulatory and competitive pressures.